Opportunities and Challenges Associated with Developing Additional Indications for Clinical Development Candidates and Marketed Drugs

Donald E. Frail, Michael J. Barratt

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Scopus citations
Original languageEnglish
Title of host publicationDrug Repositioning
Subtitle of host publicationBringing New Life to Shelved Assets and Existing Drugs
PublisherJohn Wiley and Sons
Pages33-51
Number of pages19
ISBN (Print)9780470878279
DOIs
StatePublished - Apr 8 2012

Keywords

  • Effective drug repositioning, real risks and mitigation
  • Marketed drugs, additional indications and strategies used
  • Marketed drugs, indications and challenges

Cite this

Frail, D. E., & Barratt, M. J. (2012). Opportunities and Challenges Associated with Developing Additional Indications for Clinical Development Candidates and Marketed Drugs. In Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs (pp. 33-51). John Wiley and Sons. https://doi.org/10.1002/9781118274408.ch2